Cargando…
INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)
AIMS: β‐cell stress and dysfunction may contribute to islet autoimmunity and progression to clinical type 1 diabetes. We present a protocol of three randomised controlled trials assessing the effects of glucagon‐like peptide 1 (GLP − 1) analogue liraglutide in three early stages of type 1 diabetes....
Autores principales: | Kero, Jukka, Koskenniemi, Jaakko J., Karsikas, Sara, Pokka, Tytti, Lou, Olivia, Toppari, Jorma, Veijola, Riitta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540026/ https://www.ncbi.nlm.nih.gov/pubmed/35797241 http://dx.doi.org/10.1111/dme.14913 |
Ejemplares similares
-
Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA
por: Martinez, Maria Månsson, et al.
Publicado: (2020) -
Extended family history of type 1 diabetes in HLA‐predisposed children with and without islet autoantibodies
por: Kuusela, Salla, et al.
Publicado: (2020) -
First-emerging islet autoantibody and glucose metabolism: search for type 1 diabetes subtypes
por: Helminen, Olli, et al.
Publicado: (2022) -
Early glucose metabolism in children at risk for type 1 diabetes based on islet autoantibodies compared to low-risk control groups
por: Helminen, Olli, et al.
Publicado: (2022) -
Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes
por: Hirvonen, M. Karoliina, et al.
Publicado: (2023)